Search Medical Condition
Please enter condition
Please choose location from dropdown

COVID-19 Clinical Trials

A listing of COVID-19 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (718) clinical trials

Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)

The rapid spread of COVID-19 has overwhelmed the capabilities of the Public Health System in major nations due to the large number of critically ill patients and patients seriously affected requiring intensive care. Reducing the viral load, along with other epidemiological measures, including social isolation and quarantine, may in the …


Study of COVID-19 DNA Vaccine (AG0301-COVID19)

This is a Phase 1/2, single-center, non-randomised, open-label, non-controlled trial. Approximately 30 healthy volunteers, male or female, aged 20-65, will be enrolled in the low dose group for the first 15 and the high dose group for the remaining 15. Low dose group: 1.0 mg AG0301-COVID19 intramuscular (IM) (n = …


Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context

Compare the resting energy expenditure of COVID-19 patients (obese or non-obese) in intensive care unit with mechanical ventilation to a control group of non-COVID-19 intensive care patients.

Phase N/A

BCG Vaccination to Protect Healthcare Workers Against COVID-19

Healthcare workers are at the frontline of the coronavirus disease (COVID-19) pandemic. They will be randomised to receive a single dose of BCG vaccine or 0.9% NaCl placebo. Participants will be followed-up for 12 months with notification from a Smartphone application (up to daily when ill) and surveys to identify …


Short Term High Dose Vitamin D Supplementation for COVID-19

The role of therapeutic vitamin D supplementation in asymptomatic individuals with vitamin-D deficiency and COVID-19 is not known. Immune-modulatory effect of vitamin D is likely to be observed at 25(OH)D levels which are considered higher than that required for normal bone metabolism.[6] An earlier SARS-CoV-2 negativity may have significant public …

Phase N/A

Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)

Coronavirus disease 2019 (COVID-19) is an acute respiratory syndrome caused by the novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Severe COVID-19 infection is associated with a hyper-inflammatory response and evidence of innate immune cell activation. Bruton tyrosine kinase (BTK) plays a central role in innate immune cell signaling and …

Phase N/A

A Study to Evaluate the Safety Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19

This is a randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics (PK), safety, and antiviral effects of galidesivir administered via intravenous (IV) infusion vs. placebo in hospitalized adult subjects with either Yellow Fever (Group A) or COVID-19 (Group B). The study will be conducted in two parts, and each Group …


A Study of LY3819253 (LY-CoV555) in Participants With Early Mild to Moderate COVID-19 Illness

The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus …


PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)

Rationale The novel coronavirus disease (COVID-19) pandemic is rapidly expanding across the world, with over 60.000 new cases each day as of late March 2020. Healthcare workers are struggling to provide the best care for patients with proven or suspected COVID-19. Approaches for clinical care vary widely between and within …

Phase N/A

Respiratory Physiotherapy in Severe COVID-19 Patients

COVID-19 is an infectious disease caused by SARS-CoV2 virus, that first appeared in China in 2019 and in Italy in February 2020. Approximately 80% of people infected with COVID-19 have mild to moderate disease with few symptoms, while more than 10% develop a severe disease that can lead to hypoxic …

Phase N/A